Google has become as much of a necessity to modern life as eating.Google’s search is a learning curve and odd one, too. WeYou use it every day, but very few of us actually use it to its full potential. With that being said, the search engine has plenty of tricks up its sleeve. If you want to streamline your search, it’s time to start implementing these 6 simple Google tricks.
Social media has become one of biggest marketing tools on the Internet with Facebook being at the forefront of this marketing revolution. There are however, guidelines and policies on how to use Facebook and when these are violated, you stand the chance of having your account blocked.
Around the world, lists of patients in need of an organ transplant are often longer than the lists of those willing (and able) to donate — in part because some of the most in-demand organs for transplant can only be donated after a person has died. By way of example, recent data from the British Heart Foundation (BHF) showed that the number of patients waiting for a heart transplant in the United Kingdom has grown by 162 percent in the last ten years.
Researchers at Queen’s University in Canada have managed to get a special type of bacteria to swim against a strong current, opening up the possibility of using the organisms as drug delivery vehicles. The team is using magnetotactic bacteria which have magnetic crystals within them and naturally orient themselves with the Earth’s magnetic field. By setting up the external magnetic field, the researchers were able to coax the bacteria to move in predictable ways and directions.
Most U.S. hospitals have a broad portfolio of digital technologies already in place and other innovations in early development or deployment stages, but far fewer qualify as so-called smart hospitals.
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced that the European Commission (EC) granted Marketing Authorization for lyophilized ONCASPAR (pegaspargase), as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL) in pediatric patients from birth to 18 years, and in adult patients.1 The approval – which authorizes Shire to market lyophilized ONCASPAR in the 28 member states of the European Union (EU), as well as Iceland, Liechtenstein and Norway – follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12.
The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study
Ionis Pharmaceuticals, Inc. (IONS) announced today that Roche has exercised its option to license IONIS-HTTRx following the completion of a Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in people with Huntington's disease (HD). Roche will now be responsible for all development and commercial activities. IONIS-HTTRx is the first therapy in clinical development designed to target the underlying cause of HD by reducing the production of the toxic mutant huntingtin protein (mHTT). In conjunction with the decision to license IONIS-HTTRx, Ionis earned a $45 million license fee from Roche.
Sometimes even the experts need a little help staying holly and jolly. Research shows holiday season stress can feel insurmountable. No one is immune. Mental health professionals, who are usually helping others manage emotions, put their own advice into practice as the year winds down.
Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive (M+) advanced non-small cell lung cancer (NSCLC). Data from approximately 190 patients who received tyrosine kinase inhibitors (TKI) – afatinib* in first-line, followed by second-line osimertinib**as part of standard clinical practice – will be analysed to determine total time on treatment.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.